Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (261)	11/18/2003 11:48:32 AM
From: rkrw	Read Replies (1) \| Respond to of 416

I agree with your comments. Harp (DB) is taking it too far imo. I'm surprised at how rash he's being. $15 would take medi to a PE <20 and <4X sales. This was Wyeth/Medi's first season selling flumist. There's probably a learning curve and I think it's far too soon to call flumist a bust. And if Harp is right, all they have to do is lower the price! Just a minor correction to your prior post, if I heard Young correctly on the cfsb replay: the numax timeline guidance was: Phase I adult healthy, now phase I pediatric, this coming RSV season (03/04) phase II southern hemisphere summer 04 phase II northern hemisphere Winter 04/05 *phase III pivotal superiority study Winter 05/06